ARTICLE F&A Alternative Proteins Edition October 2023 31 Emerging protein technologies, like precision biologics, have the potential to provide targeted disease prevention against costly pathogens. Precision biologics will be best delivered by their incorporation with other feed additives, such as alternative proteins or probiotics. This takes a synergistic approach to combating disease while meeting the growing demand for protein sources. Industry and researchers continue to discover and invest in the development of alternatives to antibiotics. The best solutions for livestock and aquaculture production in the absence of antibiotics will be a combination of varying strategies, from management to feed additives that strengthen gut health. Yeast extract, probiotics, and algae are examples of these feed additives that indirectly prevent diseases by improving gut health and intestinal immune function. However, many health enhancing feed additives lack specificity for particular pathogens when considered as antibiotic alternatives. This underscores the need for targeted solutions that not only prevent diseases but also uphold sustainability without posing risks of spreading antimicrobial resistance. SMALL BUT MIGHTY PROTEINS Antibodies are proteins produced by organisms with adaptive immune systems in response to an infection. These protective proteins have the ability to bind specifically to a component of a pathogen. Similarly, NovoBind’s precision biologics (NBXs) are small proteins that are derived from the binding region of a unique single-domain antibody type found in camels and llamas and are also known as nanobodies. Like conventional antibodies, NBXs bind in a specific and strong manner to its target to neutralize their function. NovoBind pioneers groundbreaking technology in the development of unique nanobodies designed to target the virulence factors found in pathogens. These virulence factors are crucial components that pathogens employ to initiate and promote infections. The company’s innovative approach encompasses a meticulous process that begins with the immunization of a llama using a purified virulence factor. Over time, blood samples are collected, and proprietary phage display technology comes into play, generating a multitude of NBX sequences. Top performing NBXs are then selected for clinical studies by screening for binding strength, stability in gut fluid, and functionality in in vitro assays. A SUSTAINABLE ALTERNATIVE Traditional antibiotics frequently kill or impair bacterial growth, which puts pressure on the development of resistance. This occurs when certain bacPRECISION BIOLOGICS – THE CATALYSTS OF CHANGE IN DISEASE PREVENTION Dr. Sarah Zaytsoff Poultry Scientist NovoBind Livestock Therapeutics
RkJQdWJsaXNoZXIy MTUxNjkxNQ==